Tata Teleservices (Maharashtra) shares plunged on Friday, giving up some gains after rallying 19% in the previous session following its Q2 results. The stock fell to Rs 34.24 on the NSE. The company reported a net loss of Rs 59 crore in Q2 FY27, narrowing from Rs 321 crore a year earlier and Rs 72 crore in the previous quarter. Despite the improvement, the stock has declined over 30% in 2026 so far and 59% in three years.
Smallcap and midcap stocks plunged up to 4% on Friday, extending a sharp weekly selloff as analysts warned that valuations remain difficult to justify. The Nifty Smallcap 250 index has fallen around 8% this week, while the Nifty Midcap 100 is down 6%, despite a resilient earnings growth outlook.
Cyient shares surged on Friday after the company reported a 25% year-on-year rise in consolidated revenue to Rs 2,235 crore in Q2 FY27. Net profit declined 8% to Rs 132 crore. The board declared an interim dividend of Rs 12 per share, while its DET business reported stronger revenue and order intake.
Silver ETFs tumble up to 4% as India permits 6,500 metric tonnes of silver imports over six months, raising expectations of easing domestic supply tightness and premiums. Higher interest rates, bond yields and a firm dollar add to pressure on bullion prices.
Japanese government bonds saw a rally on Friday, leading to the benchmark 10-year yield hitting a two-month low. This surge occurred in response to a global selloff in tech stocks, prompting investors to flock to safer investment options. The approaching Bank of Japan policy meeting is the center of attention as market watchers analyze the implications for inflation and possible interest rate shifts.
Infinx Technology Solutions has appointed Kotak Mahindra Capital, Nomura and Avendus to manage its proposed $300 million IPO, targeting FY28. Backed by KKR and Norwest Venture Partners, the healthcare IT firm provides AI-powered revenue cycle management services and has expanded through strategic investments and acquisitions, including i3 Verticals’ healthcare business.
Moderna shares plunged after detailed cancer vaccine trial results triggered profit-taking despite reducing melanoma recurrence risk by 42%. Investors weigh commercial prospects, regulatory timelines, and future oncology opportunities.
MF Performance
Major Indices
